New therapeutic target for melanoma identified

Apr 16, 2009

A protein called Mcl-1 plays a critical role in melanoma cell resistance to a form of apoptosis called anoikis, according to research published this week in Molecular Cancer Research.

The presence of Mcl-1 causes cell resistance to anoikis. This resistance to anoikis enables the cells to metastasize and survive at sites distant from the primary tumor, according to Andrew Aplin, Ph.D., an associate professor of Biology at Jefferson Medical College of Thomas Jefferson University, and a member of the Kimmel Cancer Center at Jefferson. The research was conducted at Albany Medical College in New York by Dr. Aplin and colleagues.

Mcl-1 is part of the Bcl-2 family, and is regulated by B-RAF proteins, which are mutated in approximately 60 percent of all human melanomas. The Bcl-2 family includes several prosurvival proteins that are associated with the resistance of to apoptosis, or cell death. Dr. Aplin and colleagues analyzed three candidate Bcl-2 proteins: Mcl-1, Bcl-2 and Bcl-XL.

"When we depleted Mcl-1 from the tumor cells, they were susceptible to cell death," Dr. Aplin said. "Mcl-1 showed dramatic results compared to Bcl-2 and Bcl-XL, which was a surprise. Our findings show that targeting Mcl-1, which is upregulated in a majority of melanoma , could be a viable treatment strategy."

Dr. Aplin said there are therapeutic agents in development to target this protein family, but most specifically target Bcl-2 and Bcl-XL. There is one agent in development by Gemin X Biotech that targets Mcl-1. This agent, called obatoclax, is currently in phase I/II trials.

Source: Thomas Jefferson University (news : web)

Explore further: Adding chemotherapy to radiation treatment not effective in treating vulvar cancer

add to favorites email to friend print save as pdf

Related Stories

Researchers turn cancer friend into cancer foe

Oct 07, 2008

Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer. ...

New clues about mitochondrial 'growth spurts'

Mar 02, 2009

Mitochondria are restless, continually merging and splitting. But contrary to conventional wisdom, the size of these organelles depends on more than fusion and fission, as Berman et al. show. Mitochondrial ...

Cancer cell 'bodyguard' turned into killer

Nov 25, 2008

If you're a cancer cell, you want a protein called Bcl-2 on your side because it decides if you live or die. It's usually a trusted bodyguard, protecting cancer cells from programmed death and allowing them to grow and form ...

A potential sugar fix for tumors

Apr 16, 2008

Researchers at the Duke School of Medicine apparently have solved the riddle of why cancer cells like sugar so much, and it may be a mechanism that could lead to better cancer treatments.

Recommended for you

User comments : 0